Exploitation of Unconventional CD8 T-Cell Responses Induced by Engineered Cytomegaloviruses for the Development of an HIV-1 Vaccine
Bruton J. and Hanke T., (2025), Vaccines, 13, 72 - 72
In danger: HIV vaccine research and development in Europe.
Tatoud R. et al, (2025), PLOS global public health, 5
Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa
Chanda C. et al, (2025), The Lancet Microbe
Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.
Del Moral-Sánchez I. et al, (2024), NPJ Vaccines, 9
Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions.
Kopycinski J. et al, (2023), Sci Rep, 13
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
Bailón L. et al, (2022), Nature medicine
Specific human cytomegalovirus signature detected in NK cell metabolic changes post vaccination.
Woods E. et al, (2021), NPJ vaccines, 6
Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines
Wee EG. et al, (2021), Molecular Therapy - Methods & Clinical Development, 21, 741 - 753
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
Fidler S. et al, (2020), Lancet (London, England), 395, 888 - 898
Novel Nested Peptide Epitopes Recognized by CD4+ T Cells Induced by HIV-1 Conserved-Region Vaccines.
Borthwick N. et al, (2020), Vaccines, 8
HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).
Mothe B. et al, (2020), Frontiers in Immunology, 11
In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial.
Rosás-Umbert M. et al, (2020), Frontiers in immunology, 11
Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials
Hanke T., (2019), Expert Review of Vaccines, 1 - 13
Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.
Wee EG. et al, (2019), Mol Ther Methods Clin Dev, 14, 148 - 160
Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.
Kilpeläinen A. et al, (2019), Vaccines (Basel), 7
MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice
Broset E. et al, (2019), Molecular Therapy - Methods and Clinical Development, 13, 253 - 264
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).
Mothe B. et al, (2019), EClinicalMedicine, 11, 65 - 80
Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA
Moyo N. et al, (2019), Molecular Therapy - Methods and Clinical Development, 12, 32 - 46